Revenue
No reported data
Telomir Pharmaceuticals, Inc. (TELO)
Price—Loading quote
Net income
2022
2023
2024
2025
Free cash flow
No reported data
Total cash / debt
CashTotal debt
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Research & development | $2.4M | $2.2M | $1.6M | $833,206 |
| Operating expenses | $10.5M | $12.2M | $3.9M | $854,147 |
| Net income | −$10.4M | −$16.5M | −$13.1M | −$854,147 |
| Basic EPSper diluted share | -$0.33 | -$0.56 | $0.48 | -$0.03 |
| Diluted EPSper diluted share | -$0.33 | -$0.56 | $0.48 | -$0.03 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Aug 19, 2024Form 5 | Aminov ErezCEO and Chairman | SellCommon Stock | 200 | $6.20 | $1.2K | 29.6K |
| Aug 19, 2024Form 5 | Aminov ErezCEO and Chairman | SellCommon Stock | 200 | $6.01 | $1.2K | 29.6K |